

# Adagrasib (KRAZATI)

## Criteria for Use

### June 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the [PBM INTRAnet](#) site for further information.

### Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive adagrasib.

- Prior treatment with a KRAS G12C inhibitor
- Unmanageable drug interaction identified
- Baseline QTc >480 msec
- Baseline total bilirubin > 1.5 times the Upper Limit of Normal (ULN) [or > 3 times the ULN if associated with liver metastases or Gilbert's disease) and AST/ALT > 3 times the ULN (or > 5 times the ULN if associated with liver metastases)
- Known pregnancy
- Lactating<sup>^1</sup>

<sup>^1</sup> during and for 1 week following last dose

### Inclusion Criteria

One of the following criteria must be met.

- Diagnosis of KRAS G12C-mutated locally advanced (and ineligible for definitive therapy) or metastatic non-small cell lung cancer with at least 1 prior systemic therapy
- In combination with cetuximab for KRAS G12C-mutated locally advanced or metastatic colorectal cancer after receiving prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy

### Additional Inclusion Criteria *The answers to the following must be fulfilled to meet criteria:*

- Care for the oncologic condition provided by VA or VA Community Care oncology provider
- Goals of care and role of Palliative Care consult have been discussed and documented
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2

### Additional Inclusion Criteria *Select if applicable:*

- For females who can become pregnant and males with partners who can become pregnant: Counseling provided on potential risks vs. benefits and the use of effective contraception during therapy and for at least one week following the last dose

### Other Justification

\_\_\_\_\_